← Leaderboards
Michelle M. Butler
Microbiotix, Inc
$16,920,917
Attributed
$16,920,917
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$16,920,917 · 13
By mechanism
R44$11,725,737 · 3
R43$4,142,573 · 9
R01$1,052,607 · 1
Top collaborators
No co-investigators on record.
Most similar at Microbiotix, Inc
Same institution · by research overlap
- Terry L Bowlin$33,687,170
- John D Williams$1,382,643
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionResistanceCytotoxicityToxicologyDrug KineticsIn VivoAnalogIn VitroPharmaceutical PreparationsToxic EffectBaseCellsPre-ClinicalScaffoldSeriesChemistryRouteSafetyCause Of DeathCessation Of LifePreclinical StudyLeadTherapeutic AgentsPathogen
Grant awards (28)
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,052,607
R01 · FY2021 · AI · contact PI
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$996,798
R44 · FY2021 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$982,478
R44 · FY2021 · AI · contact PI
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$1,000,000
R44 · FY2020 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$991,947
R44 · FY2020 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$999,986
R44 · FY2019 · AI · contact PI
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$999,559
R44 · FY2019 · AI · contact PI
Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs$289,030
R43 · FY2018 · AI · contact PI
Aminospectinomycin antibacterials for the treatment of antibiotic-resistant gonorrhea and other bacterial STDs$296,845
R43 · FY2017 · AI · contact PI
Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis$981,833
R44 · FY2016 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$689,746
R44 · FY2016 · AI · contact PI
Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis$988,293
R44 · FY2015 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$643,510
R44 · FY2015 · AI · contact PI
Novel spectinamide antibiotics for the treatment of MDR/XDR tuberculosis$999,980
R44 · FY2014 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$296,322
R43 · FY2013 · AI · contact PI
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$291,083
R43 · FY2013 · AI · contact PI
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs$299,966
R43 · FY2012 · AI · contact PI
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis$294,150
R43 · FY2012 · AI · contact PI
Novel Antibacterials Targeting Gram-negative Nonfermenters$261,038
R43 · FY2010 · AI · contact PI
Novel Antibacterials Targeting Gram-negative Nonfermenters$259,512
R43 · FY2009 · AI · contact PI
Bacterial DnaA Initiator Protein: A Target for Novel Antibiotics$293,875
R43 · FY2008 · AI · contact PI
DEVELOPMENT OF INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS DNA REPLICATION$261,439
R43 · FY2007 · AI · contact PI
DEVELOPMENT OF INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS DNA REPLICATION$289,344
R43 · FY2006 · AI · contact PI
BACTERIAL DNA POLYMERASES: TARGET FOR NOVEL ANTIBIOTICS$690,063
R44 · FY2005 · AI
DEVELOPMENT OF SCREENS FOR BACILLUS ANTHRACIS TARGETS$386,681
R43 · FY2005 · AI
BACTERIAL DNA POLYMERASES: TARGET FOR NOVEL ANTIBIOTICS$761,544
R44 · FY2004 · AI
A NOVEL THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS$398,997
R43 · FY2003 · AI
BACTERIAL DNA POLYMERASES: TARGETS FOR NOVEL ANTIBIOTIC$224,291
R43 · FY2001 · AI